General Home Investors News Pipeline

MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM

By MedincellSeptember 1, 2021March 15th, 2024No Comments

MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM

September 1, 2021

Previous PostMedinCell releases the results of its September 9, 2021 ordinary annual and extraordinary general meeting
Next PostVideoconference • Portfolio update

Better medicine for all

Website by ScreenUp